Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML Sutro Biopharma, Inc. Fri, Nov 1, 2024, 8:00 AM 7 min read ...

“We are excited to announce the initiation of our second pivotal trial, the registration-enabling clinical trial of luvelta in infants and toddlers with a rare and aggressive form of leukemia,” said ...

A suite of information for GP partners, practice managers and doctors to use to ensure your practice is compliant and delivering the best patient care. Safe working and managing workload in general ...

"We are excited to announce the initiation of our second pivotal trial, the registration-enabling clinical trial of luvelta in infants and toddlers with a rare and aggressive form of leukemia,” said ...